BeiGene was among the first China-based biotech companies to list on Nasdaq and made history by raising $903 million in its secondary listing in Hong Kong. Now, it’s ready to pull a hat trick as it…
Just a month after it seemed like negotiations were getting nowhere fast on waiving the intellectual property around Covid-19 vaccines ahead of a December deadline, as part of efforts to get more shots in the arms of people in low- and middle-income countries, the European Commission has now gone from
Amidst a push to ease pressure on the supply chain domestically, BD Biosciences will expand at the San Diego Reagent Innovation Center, as the property developer announced the company’s plans Monday.…
Pfizer is suing its former associate director of clinical statistics in a California court after she uploaded thousands of files to her personal Google drive in October and then misled the company…
The FDA has slapped a clinical hold on the early-stage program for one of Kura’s cancer drugs following a patient’s death in a clinical trial. The biotech $KURA reported early Wednesday that the Phase…
Months after announcing plans to build a new manufacturing campus in Hopewell, NJ, BeiGene has closed on the 42-acre site at the Princeton West Innovation Park Tuesday. The company, which is focused…
After a wild two-decade ride, the FDA has approved Takeda’s antiviral maribavir — now marketed as Livtencity — for cytomegalovirus, one of the most common viral infections experienced by transplant…
President Biden’s nominee to run the FDA was hit with some tepid criticism back in 2016 for being too cozy with the biopharma industry because some of the trials he ran had industry sponsors and some…
Philips raised the curtain on a new portfolio of smart MRI machines equipped with artificial intelligence programs to help speed up image acquisition and diagnosis as well as a new scanner combining…
As it nears the halfway point of its BD2025 plan to accelerate companywide growth and stakeholder value, BD has tapped a seasoned exec from one of its competitors to oversee all investor-facing…
